Headlines about SCYNEXIS (NASDAQ:SCYX) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. SCYNEXIS earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.6486000268677 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern’s rankings:
- Scynexis Inc (SCYX) Share Activity Climbing in Session – Lockport Press (lockportpress.com)
- ETFs with exposure to SCYNEXIS, Inc. : November 10, 2017 (finance.yahoo.com)
- Boston Scientific Corporation (BSX) registers a price change of 0.50% while SCYNEXIS, Inc. (SCYX) finishes with a … – Stocks Gallery (stocksgallery.com)
- SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update (finance.yahoo.com)
- Scynexis reports 3Q loss (finance.yahoo.com)
SCYNEXIS (NASDAQ SCYX) traded down $0.08 during trading hours on Tuesday, reaching $1.68. 259,800 shares of the company traded hands, compared to its average volume of 343,610. SCYNEXIS has a 1 year low of $1.52 and a 1 year high of $4.04. The company has a quick ratio of 7.30, a current ratio of 7.30 and a debt-to-equity ratio of 0.43.
SCYX has been the subject of several recent analyst reports. Zacks Investment Research raised shares of SCYNEXIS from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a report on Tuesday. HC Wainwright set a $14.00 price objective on shares of SCYNEXIS and gave the stock a “buy” rating in a report on Wednesday, August 16th. Roth Capital set a $9.00 price objective on shares of SCYNEXIS and gave the stock a “buy” rating in a report on Monday, August 7th. Finally, Guggenheim initiated coverage on shares of SCYNEXIS in a report on Tuesday, October 24th. They set a “buy” rating and a $6.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $8.43.
ILLEGAL ACTIVITY WARNING: This story was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://sportsperspectives.com/2017/11/14/scynexis-scyx-earns-daily-media-sentiment-rating-of-0-13.html.
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.